<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8800478</journal-id>
<journal-id journal-id-type="pubmed-jr-id">1990</journal-id>
<journal-id journal-id-type="nlm-ta">Brain Behav Immun</journal-id>
<journal-id journal-id-type="iso-abbrev">Brain Behav. Immun.</journal-id>
<journal-title-group>
<journal-title>Brain, behavior, and immunity</journal-title>
</journal-title-group>
<issn pub-type="ppub">0889-1591</issn>
<issn pub-type="epub">1090-2139</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27395435</article-id>
<article-id pub-id-type="pmc">5218993</article-id>
<article-id pub-id-type="doi">10.1016/j.bbi.2016.07.003</article-id>
<article-id pub-id-type="manuscript">NIHMS805472</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Inflammation in Alzheimer’s Disease: Lessons learned from microglia-depletion models</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Spangenberg</surname>
<given-names>Elizabeth E.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Green</surname>
<given-names>Kim N.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Neurobiology and Behavior, Institute for Memory Impairments and Neurological Disorders</aff>
<author-notes>
<corresp id="FN1"><underline>Address correspondence to:</underline> Kim N. Green, Ph.D., 3208 Biological Sciences III, University of California, Irvine, Irvine, CA 92697-4545, Tel: 949 824 3859, <email>kngreen@uci.edu</email></corresp>
<fn fn-type="COI-statement" id="FN3">
<p>
<bold>Conflict of Interest</bold>
</p>
<p>The authors E.E.S and K.N.G have no conflicting financial interests.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>26</day>
<month>7</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>06</day>
<month>7</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>3</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>3</month>
<year>2018</year>
</pub-date>
<volume>61</volume>
<fpage>1</fpage>
<lpage>11</lpage>
<!--elocation-id from pubmed: 10.1016/j.bbi.2016.07.003-->
<abstract>
<p id="P1">Microglia are the primary immune cell of the brain and function to protect the central nervous system (CNS) from injury and invading pathogens. In the homeostatic brain, microglia serve to support neuronal health through synaptic pruning, promoting normal brain connectivity and development, and through release of neurotrophic factors, providing support for CNS integrity. However, recent evidence indicates that the homeostatic functioning of these cells is lost in neurodegenerative disease, including Alzheimer’s disease (AD), ultimately contributing to a chronic neuroinflammatory environment in the brain. Importantly, the development of compounds and genetic models to ablate the microglial compartment has emerged as effective tools to further our understanding of microglial function in AD. Use of these models has identified roles of microglia in several pathological facets of AD, including tau propagation, synaptic stripping, neuronal loss, and cognitive decline. Although culminating evidence utilizing these microglial ablation models reports an absence of CNS-endogenous and peripheral myeloid cell involvement in Aβ phagocytosis, recent data indicates that targeting microglia-evoked neuroinflammation in AD may be essential for potential therapeutics. Therefore, identifying altered signaling pathways in the microglia-devoid brain may assist with the development of effective inflammation-based therapies in AD.</p>
</abstract>
<kwd-group>
<kwd>Microglia</kwd>
<kwd>Colony-stimulating factor 1 receptor</kwd>
<kwd>Inflammation</kwd>
<kwd>Alzheimer’s disease</kwd>
<kwd>Amyloid</kwd>
<kwd>Tau</kwd>
<kwd>Spines</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>